Get started
Author

Kristen E. Hurov

ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage
2007 · Shuhei Matsuoka, Bryan A. Ballif, et al. · Science · 3,146
Identification of the FANCI Protein, a Monoubiquitinated FANCD2 Paralog Required for DNA Repair
2007 · Agata Smogorzewska, Shuhei Matsuoka, et al. · Cell · 718
PDF
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
2017 · E. Robert McDonald, Antoine de Weck, et al. · Cell · 649
PDF
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
2016 · Konstantinos J. Mavrakis, E. Robert McDonald, et al. · Science · 618
A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage
2010 · Danny M. Chou, Britt Adamson, et al. · Proceedings of the National Academy of Sciences · 557
A Role for Proapoptotic BID in the DNA-Damage Response
2005 · Sandra S. Zinkel, Kristen E. Hurov, et al. · Cell · 244
PDF
A DNA Damage Response Screen Identifies RHINO, a 9-1-1 and TopBP1 Interacting Protein Required for ATR Signaling
2011 · Cecilia Cotta-Ramusino, E. Robert McDonald, et al. · Science · 229
A genetic screen identifies the Triple T complex required for DNA damage signaling and ATM and ATR stability
2010 · Kristen E. Hurov, Cecilia Cotta-Ramusino, et al. · Genes & Development · 214
PDF
NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control
2009 · Bin Wang, Kristen Hurov, et al. · Genes & Development · 177
PDF
Rad17 Phosphorylation Is Required for Claspin Recruitment and Chk1 Activation in Response to Replication Stress
2006 · Xin Wang, Lee Zou, et al. · Molecular Cell · 138
PDF
Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer
2013 · Mohamed E. Abazeed, Drew J. Adams, et al. · Cancer Research · 128
Response of small intestinal epithelial cells to acute disruption of cell division through CDC25 deletion
2009 · Gwanghee Lee, Lynn S. White, et al. · Proceedings of the National Academy of Sciences · 85
Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology Insight
2016 · B. Barry Touré, John Giraldes, et al. · Journal of Medicinal Chemistry · 55
PDF
Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling
2014 · Marie Schoumacher, Kristen E. Hurov, et al. · Cancer Research · 46
BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism
2021 · Kristen Hurov, Johanna Lahdenranta, et al. · Journal for ImmunoTherapy of Cancer · 39
PDF
Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist
2021 · Punit Upadhyaya, Johanna Lahdenranta, et al. · Journal for ImmunoTherapy of Cancer · 32
PDF
Bid Plays a Role in the DNA Damage Response
2007 · Sandra S. Zinkel, Kristen E. Hurov, et al. · Cell · 26
PDF
Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology
2022 · Punit Upadhyaya, Julia Kristensson, et al. · Journal of Medicinal Chemistry · 21
“Addition” and “Subtraction”: Selectivity Design for Type II Maternal Embryonic Leucine Zipper Kinase Inhibitors
2017 · Xin Chen, John Giraldes, et al. · Journal of Medicinal Chemistry · 11
PDF
Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer
2013 · M. Abazeed, D. Adams, et al. · International Journal of Radiation Oncology*Biology*Physics · 10
706 BT7480, a fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonism and modulation of tumor immune microenvironment
2020 · Punit Upadhyaya, Kristen Hurov, et al. · Journal for ImmunoTherapy of Cancer · 3
Abstract LB-017: Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to marked dependence on PRMT5
2016 · Konstantinos Mavrakis, E Robert McDonald, et al. · Cancer Research · 3
A combined phase I/II study of a novel bicycle tumor-targeted immune cell agonist BT7480 in patients with nectin-4 associated advanced malignancies.
2022 · Kyriakos P. Papadopoulos, Afshin Dowlati, et al. · Journal of Clinical Oncology · 2
Abstract 5552: BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICATM) induces tumor localized 4-1BB agonism
2020 · Kristen Hurov, Punit Upadhyaya, et al. · Cancer Research · 2
2 Quantitation of CD137 and Nectin-4 expression across multiple tumor types to support indication selection for BT7480, a Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™)
2021 · Heather Cohen, Carly Campbell, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Works count: 66
Citation count: 7,155
H-index: 18
I10-index: 20
Year
Topic
Type